NLM Digital Collections

Search

Start Over Subjects Drug Therapy, Combination ✖Remove constraint Subjects: Drug Therapy, Combination

1. Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States

2. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

3. Controversies in the management of patients with type 2 diabetes: final report

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 2014
Subject(s):
Comparative Effectiveness Research
Diabetes Mellitus, Type 2 -- drug therapy
Disease Management
Blood Glucose -- analysis
Blood Glucose -- metabolism
Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
Drug Therapy, Combination
Hemoglobin A, Glycosylated -- analysis
Hypoglycemic Agents -- administration & dosage
Hypoglycemic Agents -- therapeutic use
Insulin -- therapeutic use
Metformin -- administration & dosage
Metformin -- therapeutic use
Monitoring, Ambulatory
Randomized Controlled Trials as Topic
Receptors, Glucagon -- agonists
Sulfonylurea Compounds -- administration & dosage
Sulfonylurea Compounds -- therapeutic use
Treatment Outcome
Humans
New England
United States

4. Severely debilitating or life-threatening hematologic disorders: nonclinical development of pharmaceuticals

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, March 2019
Subject(s):
Drug Evaluation, Preclinical -- standards
Hematologic Diseases -- drug therapy
Animals
Carcinogenicity Tests
Cytotoxicity Tests, Immunologic
Drug Therapy, Combination
Drug-Related Side Effects and Adverse Reactions
Immunologic Tests
Mutagenicity Tests
Pediatrics
Pharmacokinetics
Photochemistry
Safety
Toxicity Tests
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

5. Reducing potential overuse of dementia drugs could lead to considerable savings

Author(s):
Carter, Elizabeth A., author
Purvis, Leigh, author
Publication:
Washington, DC : AARP Public Policy Institute, August 2018
Subject(s):
Dementia -- drug therapy
Dementia -- economics
Drug Costs
Inappropriate Prescribing -- economics
Aged
Cholinesterase Inhibitors -- economics
Cholinesterase Inhibitors -- therapeutic use
Cost Savings
Drug Therapy, Combination
Memantine -- economics
Memantine -- therapeutic use
Humans
United States

7. AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report

Author(s):
Makam, Anil N., author
Nikitin, Dmitriy, author
Richardson, Marina, author
Mohammed, Rasheed, author
McKenna, Avery, author
Pearson, Steven D., author
Rind, David M., author
Suh, Kangho, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, September 13, 2022
Subject(s):
Amyotrophic Lateral Sclerosis -- drug therapy
Drug Therapy, Combination
Edaravone -- therapeutic use
Phenylbutyrates -- therapeutic use
United States